

Welcome

Annual General Meeting Carl Zeiss Meditec AG

Thursday, 21 March 2024



348.1

million Euro EBIT in fiscal year 2022/23

16.7%

EBIT margin in fiscal year 2022/23



Ophthalmology

Microsurgery



million Euro revenue in fiscal year 2022/23



million Euro revenue in fiscal year 2022/23



sales growth



sales growth





27.3 % of total revenue

APAC

1,001.2 million Euro sales

+4.6% sales growth

EMEA

517.3 million Euro sales

+12.7%

sales growth

Americas

570.7 million Euro sales



sales growth



million Euro revenue in fiscal year 2022/23

























.























ZEISS ATLAS 500

corneal topography system

ZEISS AT ELANA 841P

hydrophobic trifocal IOL



ZEISS VISULAS combi

laser for photocoagulation

Customer Focus



By 2050, number of people over 60 years will rise to over



10 Million

qualified healthcare professionals will be in shortage worldwide in 2030



Our partnership enables us to develop precision therapies to deliver the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs.

Ulrike Graefe-Mody, Ph.D. Head of Retinal Health, Boehringer Ingelheim



Customer Focus






ZEISS has enabled Artificial Intelligence analytics in ophthalmic diagnostic devices for over 25 years. For example, the early Swedish Interactive Thresholding Algorithm (SITA) introduced in the late-1990s is considered AI of US Food and Drug Administration definition.

SITA allows faster test time in ZEISS Humphrey Field Analyzer (HFA) threshold testing.

New generation of Perimetry **ZEISS Humphrey Field Analyzer 3** with SITA

EN_31_150_01121



ZEINN



of sales invested in research & development



LONG-TERM CORPORATE STRATEGY

ZEISS Retina Workflow

Assess & educate

ZEISS SL 800 and SL Imaging Solution

Plan. ZEISS CIRRUS OCT 6000 ZEISS CLARUS 700

Treat. ZEISS VISULAS Green ZEISS ARTEVO 800

=

Check ZEISS Retina Workplace



ZANK

dividend per share



Share Buyback Program



Volume

February 9, 2024

up to 150 million €*

~ 1,7 %

of share capital (status January 29, 2024)

* dependent on share price performance and development of net liquidity

Purchased to date

164,200 shares



475.0

million Euro revenue in Q1 2023/24



revenue growth yoy



million Euro EBIT



EBIT margin







Thank you!



Annual General Meeting Carl Zeiss Meditec AG